semaglutide produces 14.9% body weight loss in obese adults at the wegovy dose (2.4 mg subcutaneous, weekly), per STEP 1 in NEJM 2021. it's fda-approved as wegovy for chronic weight management. SELECT (NEJM 2023) added a 20% reduction in major adverse cardiovascular events. the trial record on semaglutide for obesity is the heaviest in the GLP-1 class.
the efficacy crown belongs to tirzepatide (22.5% in SURMOUNT-1) and retatrutide (24.2% in phase 2). semaglutide keeps three other titles: the longest FDA-monitored safety record (15+ years on ozempic for diabetes), the deepest cardiovascular evidence base (SELECT), and the brand recognition of ozempic and wegovy.
what the STEP trials actually showed.
the STEP program ran multiple phase-3 trials, all randomized double-blind placebo-controlled, all testing semaglutide 2.4 mg weekly in different obesity populations.
the headline 14.9% is a population mean. the distribution underneath it is what readers actually want. of every 100 patients in the STEP 1 drug arm:
then SELECT changed the conversation.
this was the trial that turned the cosmetic-drug argument into a medical-drug argument. semaglutide is now a cardiovascular drug as well as a weight-loss drug. the implications for insurance coverage, FDA labeling, and clinical practice are still working out.
how it works.
semaglutide is a synthetic analog of glucagon-like peptide-1, modified for protease resistance and albumin-binding to extend half-life from ~2 minutes (native GLP-1) to ~7 days. once-weekly subcutaneous injection.
the mechanism that drives weight loss is multi-target:
1. delayed gastric emptying. food sits in the stomach longer. people feel full sooner and stay full longer.
2. central satiety signaling. GLP-1 receptors in the hypothalamus signal "you're satisfied" to the brain.
3. food noise reduction. reduces the brain's reward response to highly palatable food, documented in human fMRI work on GLP-1 receptor agonists. compulsive food-thought patterns quiet down.
4. insulin sensitization. improves glycemic control as a downstream effect, which is why ozempic existed before wegovy.
the alcohol indication that just hit the lancet (klausen et al. 2026) is the same mechanism extended to a different reward. semaglutide reduces the brain's reward response to alcohol the same way it does to food.
versus tirzepatide and retatrutide.
ranked by published weight-loss efficacy:
tirzepatide: 22.5% body weight loss at top dose, SURMOUNT-1, NEJM 2022. dual GIP/GLP-1 agonist. fda-approved as zepbound (obesity) and mounjaro (diabetes).
retatrutide: 24.2% at 48 weeks in phase 2, jastreboff 2023. triple GIP/GLP-1/glucagon agonist. not yet fda-approved.
semaglutide: 14.9% in STEP 1.
tirzepatide is the new top of the field for efficacy. retatrutide will reset that floor again when phase 3 finishes. but semaglutide has the longest fda-monitored safety record and the deepest cardiovascular dataset. as an evidence map: tirzepatide leads published efficacy, semaglutide leads evidence depth, retatrutide is still trial-stage.
what the safety record says.
the published safety profile, as reported in the STEP and SELECT trials:
gastrointestinal. nausea (40%+ at initiation), vomiting (15-25%), diarrhea, constipation. dose-dependent and usually transient over 4-8 weeks. listed as common adverse events on the FDA label.
muscle / lean mass loss. roughly 25-40% of total mass lost is lean tissue, similar to what diet-only weight-loss studies report. ongoing research on the role of resistance training and adequate protein intake alongside the drug in trial settings.
gallbladder. increased risk of cholelithiasis. rare but elevated vs placebo.
pancreatitis. rare. listed as a precaution.
medullary thyroid carcinoma. contraindicated for personal or family history of MTC or MEN2.
suicidal ideation. surveilled. fda 2024 review found no causal link.
common mistakes.
1. titration too fast. the semaglutide titration schedule (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) exists because GI side effects are dose-dependent. patients who push faster usually quit on side effects. patients who titrate slowly tolerate the drug.
2. lean mass. the 25-40% lean-mass loss is real. in the studies, participants who added resistance training and higher protein intake (~1.2-1.6 g/kg body weight in the published protocols) preserved more lean mass than the drug alone.
3. stopping cold turkey. SURMOUNT-4 and STEP 4 both report participants regain a meaningful fraction of lost weight after discontinuation. this is a chronic-disease pattern, not a "course" of treatment.
4. assuming brand-name versions are different molecules. ozempic, wegovy, and the compounded versions are all semaglutide. different doses, different fda labels, different supply chains. same compound.
questions people actually ask.
is semaglutide the same as ozempic? semaglutide is the molecule. ozempic is the brand name for the diabetes-indication formulation (0.25-2.0 mg). wegovy is the brand name for the obesity-indication formulation (up to 2.4 mg). same compound, different dose, different fda labels.
does semaglutide work without diet changes? the trials all included lifestyle counseling alongside the drug. published data on drug-only effects is limited. realistic answer: semaglutide quiets food noise enough that most people eat less spontaneously. adding intentional lifestyle changes increases the effect.
how long do patients stay on semaglutide? chronically, like any other treatment for a chronic disease. discontinuation typically results in regain. the chronic-disease framing is becoming the standard clinical view.
does insurance cover semaglutide for weight loss? varies. many plans cover wegovy for obesity if BMI ≥30 (or ≥27 with comorbidities). ozempic for off-label weight loss is typically not covered. cost without insurance: ~$1,000-1,400 USD per month.
how does alcohol interact with semaglutide? alcohol-related GI side effects can intensify. recent research (klausen 2026, lancet) shows semaglutide reduces alcohol consumption, especially in people with alcohol use disorder. AUD is a prescriber conversation.
what's the best GLP-1 for weight loss? by published efficacy: retatrutide phase-2 readout (24.2%, not approved) > tirzepatide (22.5%) > semaglutide (14.9%) > liraglutide (~8%). by evidence depth and cardiovascular safety: semaglutide. the right answer depends on the question.
reptides editorial · research reference, not medical advice.